Literature DB >> 3286675

Ig class and IgG subclass responses to Treponema pallidum in patients with syphilis.

R E Baughn1, J L Jorizzo, C B Adams, D M Musher.   

Abstract

The Ig class and IgG subclasses of anti-Treponema pallidum antibodies in human serum were quantified using solid-phase enzyme-linked immunosorbent assays. Development of these assays with monoclonal antibodies, each specific for a human immunoglobulin class or IgG subclass, provided quantitative data concerning the major antibody specificities. In patients with primary syphilis, anti-T. pallidum activity was limited almost exclusively to IgG1 and IgM. Coordinate, restricted expression of IgG1 and IgG3 responses in T. pallidum-specific assays was observed with sera from patients with active secondary syphilis. IgG1 and IgG3 accounted for roughly 53 and 43% of the total anti-treponemal IgG antibody activity, respectively. While IgM antibody levels were elevated in the patients with secondary syphilis, IgG2 and IgG4 levels, if present at all, represented less than 10 and 2% of the total IgG activity, respectively. Ig in sera from patients who had been treated adequately for secondary syphilis were restricted almost entirely to IgG3 and IgG1. Considering the low level of IgG3 in serum, disproportionately high percentages of antitreponemal antibodies were found in this subclass during and after treatment for secondary syphilis. The restricted, coexpression of the IgG1 and IgG3 isotypes may reflect the close genetic linkage of the gamma 1 and gamma 3 genes and possibly the impact of immunoregulatory mechanisms in response to the induction and expression of autoantibodies which arise during the course of secondary syphilis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286675     DOI: 10.1007/bf00917901

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  51 in total

1.  The pattern of immunological responses at various stages of syphilis.

Authors:  R Shannon; S D Booth
Journal:  Br J Vener Dis       Date:  1977-10

2.  IgM class antitreponemal antibody in treated and untreated syphilis.

Authors:  P O'Neill; C S Nicol
Journal:  Br J Vener Dis       Date:  1972-12

3.  The gammaG subclass of antinuclear and antinucleic acid antibodies.

Authors:  P H Schur; M Monroe; N Rothfield
Journal:  Arthritis Rheum       Date:  1972 Mar-Apr

4.  Fluorescent treponemal antibody test with antihuman immune sera of different specificity.

Authors:  K Király; R Backhausz; A Jobbágy; J Lajos; L Kováts
Journal:  Acta Derm Venereol       Date:  1968       Impact factor: 4.437

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  IgG subclass distribution of autoantibodies to DNA and to nuclear ribonucleoproteins in autoimmune diseases.

Authors:  M Zouali; R Jefferis; A Eyquem
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

7.  Immunoglobulin classes and IgG subclasses of human antinuclear antibodies. A correlation of complement fixation and the nephritis of systemic lupus erythematosus.

Authors:  E M Puritz; W J Yount; M Newell; P D Utsinger
Journal:  Clin Immunol Immunopathol       Date:  1973-11

8.  IgG4 antibodies in Egyptian patients with schistosomiasis.

Authors:  R Iskander; P K Das; R C Aalberse
Journal:  Int Arch Allergy Appl Immunol       Date:  1981

9.  Immunoglobulin G subclasses of fluorescent anti-Treponema pallidum antibodies: evidence for sequential development of specific anti-T. pallidum immunoglobulin G responses in patients with early syphilis.

Authors:  J J van der Sluis; E C van Reede; M Boer
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

10.  Enzyme-linked immunosorbent assay for detection of immunoglobulin M antibody against the Reiter treponeme flagellum in syphilis.

Authors:  N S Pedersen; C S Petersen; N H Axelsen
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

View more
  7 in total

1.  Comparison of a combined nontreponemal (VDRL) and treponemal immunoblot to traditional nontreponemal and treponemal assays.

Authors:  Alicia A Franken; Joyce H Oliver; Christine M Litwin
Journal:  J Clin Lab Anal       Date:  2014-01-03       Impact factor: 2.352

2.  Anti-Treponema pallidum IgM, IgA, and IgG subclass antibody responses after treatment in patients with syphilis at various stages: 1. Assessments by enzyme-linked immunosorbent assay.

Authors:  S Tanaka; T Suzuki
Journal:  Genitourin Med       Date:  1990-06

3.  Demonstration and immunochemical characterization of natural, autologous anti-idiotypic antibodies throughout the course of experimental syphilis.

Authors:  R E Baughn
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

Review 4.  The Th1/Th2-like switch in syphilitic infection: is it detrimental?

Authors:  T J Fitzgerald
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

5.  Immunoglobulin class and subclass restriction of autoimmune responses in secondary syphilis.

Authors:  J Versalovic; Z D Nash; R Carinhas; D M Musher; R E Baughn
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

6.  A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy.

Authors:  Arlene C Seña; Xiao-Hui Zhang; Trudy Li; He-Ping Zheng; Bin Yang; Li-Gang Yang; Juan C Salazar; Myron S Cohen; M Anthony Moody; Justin D Radolf; Joseph D Tucker
Journal:  BMC Infect Dis       Date:  2015-10-28       Impact factor: 3.090

7.  IFNγ Enhances CD64-Potentiated Phagocytosis of Treponema pallidum Opsonized with Human Syphilitic Serum by Human Macrophages.

Authors:  Kelly L Hawley; Adriana R Cruz; Sarah J Benjamin; Carson J La Vake; Jorge L Cervantes; Morgan LeDoyt; Lady G Ramirez; Daniza Mandich; Mary Fiel-Gan; Melissa J Caimano; Justin D Radolf; Juan C Salazar
Journal:  Front Immunol       Date:  2017-10-05       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.